8-K - NOVANTA INC (0001076930) (Filer)

8-K - NOVANTA INC (0001076930) (Filer)

CERT - NOVANTA INC (0001076930) (Filer)

8-A12B - NOVANTA INC (0001076930) (Filer)

424B5 - NOVANTA INC (0001076930) (Filer)

FWP - NOVANTA INC (0001076930) (Subject)

424B5 - NOVANTA INC (0001076930) (Filer)

POSASR - NOVANTA INC (0001076930) (Filer)

10-Q - NOVANTA INC (0001076930) (Filer)

8-K - NOVANTA INC (0001076930) (Filer)

4 - NOVANTA INC (0001076930) (Issuer)

3 - NOVANTA INC (0001076930) (Issuer)

4 - NOVANTA INC (0001076930) (Issuer)

4 - NOVANTA INC (0001076930) (Issuer)

4 - NOVANTA INC (0001076930) (Issuer)

4 - NOVANTA INC (0001076930) (Issuer)

4 - NOVANTA INC (0001076930) (Issuer)

4 - NOVANTA INC (0001076930) (Issuer)

4 - NOVANTA INC (0001076930) (Issuer)

4 - NOVANTA INC (0001076930) (Issuer)

William Blair upgraded Novanta from Mkt Perform to Outperform

Novanta Inc. (NASDAQ:NOVT) ("Novanta" or the "Company"), a trusted technology partner to medical and advanced technology equipment manufacturers, announced today that it has priced its previously announced public offering of 11 million of its 6.50% tangible equity units at $50.00 per unit (equal to the stated amount per unit). The transaction is a public offering made by means of a prospectus supplement under Novanta's effective shelf registration statement. Novanta's common shares are quoted on Nasdaq under the ticker symbol "NOVT," and Novanta has applied to list the tangible equity units on Nasdaq under the symbol "NOVTU." Novanta anticipates that the offering will close on November 12,

Novanta Inc. (NASDAQ:NOVT) ("Novanta" or the "Company"), a trusted technology partner to medical and advanced technology equipment manufacturers, announced today that it has commenced a public offering of 11 million tangible equity units, with an aggregate stated amount of $550.0 million. Each tangible equity unit will have a stated amount of $50.00 and be comprised of a prepaid stock purchase contract and a senior amortizing note due 2028, each issued by Novanta. The tangible equity unit offering is a public offering made by means of a prospectus supplement under Novanta's effective shelf registration statement. Novanta's common shares are quoted on Nasdaq under the ticker symbol "NOVT," a

Third Quarter 2025 GAAP Revenue increased 1.4% to $247.8 million Third Quarter 2025 GAAP Net Income of $10.7 million Third Quarter 2025 GAAP Diluted Earnings Per Share of $0.30 Third Quarter 2025 Adjusted EBITDA of $58.1 million Third Quarter 2025 Adjusted EPS of $0.87 Novanta Inc. (NASDAQ:NOVT) ("Novanta" or the "Company"), a trusted technology partner to medical and advanced technology equipment manufacturers, today reported financial results for the third quarter 2025. Financial Highlights Three Months Ended (In millions, except per share amounts) September 26,   September 27,   2025   2024 GAAP  

Novanta Inc. (NASDAQ:NOVT) (the "Company"), a trusted technology partner to medical and advanced technology equipment manufacturers, announced today that Matthijs Glastra, Chair & Chief Executive Officer is scheduled to present at Jefferies Global Healthcare Conference on Tuesday, November 18, 2025, in London. About Novanta Novanta is a leading global supplier of core technology solutions that give medical and advanced industrial original equipment manufacturers a competitive advantage. We combine deep proprietary technology expertise and competencies in precision medicine and manufacturing, medical solutions, and robotics and automation with a proven ability to solve complex technical

Novanta Inc. (NASDAQ:NOVT), a trusted technology partner to medical and advanced industrial OEMs, announced that it will host an International Organization for Standardization (ISO) working group event for humanoid robot safety standards in Barcelona, Spain, from October 27-30, 2025. This multi-year ISO initiative aims to define the safety framework guiding how humanoid robots are designed, developed, and deployed around the world. The working group will bring together 40 to 50 international experts and innovators to advance the development of global safety standards for humanoid robots, helping to define safe human/robot interaction in real-world environments. Hosting the ISO event reinf

Novanta Inc. (NASDAQ:NOVT) (the "Company"), a trusted technology partner to medical and advanced technology equipment manufacturers, announced today that Matthijs Glastra, Chair & Chief Executive Officer is scheduled to present at the Baird 2025 Global Industrial Conference on Tuesday, November 11, 2025, in Chicago, Illinois. About Novanta Novanta is a leading global supplier of core technology solutions that give medical and advanced industrial original equipment manufacturers a competitive advantage. We combine deep proprietary technology expertise and competencies in precision medicine and manufacturing, medical solutions, and robotics and automation with a proven ability to solve co

Novanta Inc. (NASDAQ:NOVT) (the "Company"), a trusted technology partner to medical and advanced technology equipment manufacturers, will release its third quarter 2025 results on Tuesday, November 4, 2025. The Company will host a conference call on Tuesday, November 4, 2025, at 8:30 a.m. ET to discuss these results. To access the call, please dial (888) 346-3959 before the scheduled conference call time. Alternatively, the conference call can be accessed online via a live webcast on the Events & Presentations page of the Investors section of the Company's website at www.novanta.com. A replay of the audio webcast will be available approximately three hours after the conclusion of the ca

Novanta Inc. (NASDAQ:NOVT) (the "Company"), a trusted technology partner to medical and advanced technology equipment manufacturers, announced today that its Board of Directors has authorized the repurchase of up to an additional $200 million of the Company's outstanding common shares, adding capacity to the $31 million remaining from its 2020 Board authorization, for a total capacity of $231 million. "The Board's action reflects continued confidence in the Company's financial strength, the execution of our growth strategy, and our ability to maximize shareholder value by deploying Novanta's cash flows to the highest returning investments available to the company," said Robert Buckley, Ch

Novanta Inc. (NASDAQ:NOVT) (the "Company"), a trusted technology partner to medical and advanced technology equipment manufacturers, announced today that Matthijs Glastra, Chair & Chief Executive Officer, and Robert Buckley, Chief Financial Officer, is scheduled to present at Baird 2025 Global Healthcare Conference on Tuesday, September 9, 2025, in New York, NY. About Novanta Novanta is a leading global supplier of core technology solutions that give medical, life science, and advanced industrial original equipment manufacturers a competitive advantage. We combine deep proprietary expertise and competencies in precision medicine, precision manufacturing, robotics and automation, and adv

Second Quarter 2025 GAAP Revenue increased 2% to $241 million Second Quarter 2025 GAAP Net Income of $4.5 million Second Quarter 2025 GAAP Diluted Earnings Per Share of $0.12 Second Quarter 2025 Adjusted EBITDA of $52 million Second Quarter 2025 Adjusted EPS of $0.76 Company updates Full Year 2025 financial guidance Novanta Inc. (NASDAQ:NOVT) ("Novanta" or the "Company"), a trusted technology partner to medical and advanced technology equipment manufacturers, today reported financial results for the second quarter 2025. Financial Highlights Three Months Ended   (In millions, except per share amounts) June 27,     June 28,

IDEX Corporation (NYSE:IEX) today announced the appointment of Stephanie ("Steph") Disher and Matthijs Glastra to the company's Board of Directors. The appointments, effective Friday, February 21, 2025, increase the size of the Board from 10 to 12 directors. Ms. Disher will serve on the Board's Nominating and Corporate Governance Committee, and Mr. Glastra will serve on the Board's Audit Committee. Ms. Disher currently serves as Chief Executive Officer of Atmus Filtration Technologies Inc. (NYSE:ATMU), a leader in filtration and media solutions. She has extensive global leadership experience in finance and operations from her time at Atmus, Cummins Inc. and BP, p.l.c. Mr. Glastra currentl

Sends Letter to Masimo Shareholders and Releases 160-Page Investor Presentation Urges Shareholders to Help Deliver Immediate Change by Voting for Both of Politan's Independent and Ideally Qualified Nominees Darlene Solomon and William Jellison on the WHITE Card Shareholders Can Visit www.AdvanceMasimo.com for Further Information Politan Capital Management (together with its affiliates, "Politan"), an 8.9% shareholder of Masimo Corporation ("Masimo" or the "Company") (NASDAQ:MASI), today sent a letter to the Company's shareholders outlining why a majority of truly independent directors are urgently needed in the Masimo boardroom. Politan also released a detailed investor presentation m

Third Quarter 2025 GAAP Revenue increased 1.4% to $247.8 million Third Quarter 2025 GAAP Net Income of $10.7 million Third Quarter 2025 GAAP Diluted Earnings Per Share of $0.30 Third Quarter 2025 Adjusted EBITDA of $58.1 million Third Quarter 2025 Adjusted EPS of $0.87 Novanta Inc. (NASDAQ:NOVT) ("Novanta" or the "Company"), a trusted technology partner to medical and advanced technology equipment manufacturers, today reported financial results for the third quarter 2025. Financial Highlights Three Months Ended (In millions, except per share amounts) September 26,   September 27,   2025   2024 GAAP  

Novanta Inc. (NASDAQ:NOVT) (the "Company"), a trusted technology partner to medical and advanced technology equipment manufacturers, will release its third quarter 2025 results on Tuesday, November 4, 2025. The Company will host a conference call on Tuesday, November 4, 2025, at 8:30 a.m. ET to discuss these results. To access the call, please dial (888) 346-3959 before the scheduled conference call time. Alternatively, the conference call can be accessed online via a live webcast on the Events & Presentations page of the Investors section of the Company's website at www.novanta.com. A replay of the audio webcast will be available approximately three hours after the conclusion of the ca

Second Quarter 2025 GAAP Revenue increased 2% to $241 million Second Quarter 2025 GAAP Net Income of $4.5 million Second Quarter 2025 GAAP Diluted Earnings Per Share of $0.12 Second Quarter 2025 Adjusted EBITDA of $52 million Second Quarter 2025 Adjusted EPS of $0.76 Company updates Full Year 2025 financial guidance Novanta Inc. (NASDAQ:NOVT) ("Novanta" or the "Company"), a trusted technology partner to medical and advanced technology equipment manufacturers, today reported financial results for the second quarter 2025. Financial Highlights Three Months Ended   (In millions, except per share amounts) June 27,     June 28,

Novanta Inc. (NASDAQ:NOVT) (the "Company"), a trusted technology partner to medical and advanced technology equipment manufacturers, will release its second quarter 2025 results on Tuesday, August 5, 2025. The Company will host a conference call on Tuesday, August 5, 2025, at 10:00 a.m. ET to discuss these results. To access the call, please dial (888) 346-3959 before the scheduled conference call time. Alternatively, the conference call can be accessed online via a live webcast on the Events & Presentations page of the Investors section of the Company's website at www.novanta.com. A replay of the audio webcast will be available approximately three hours after the conclusion of the call

First Quarter 2025 GAAP Revenue increased 1% to $233 million First Quarter 2025 GAAP Diluted Earnings Per Share of $0.59 and Adjusted EPS of $0.74 First Quarter 2025 GAAP Net Income increased 45% to $21 million First Quarter 2025 Adjusted EBITDA increased 1% to $50 million First Quarter 2025 Operating Cash Flow of $32 million Company reiterates Full Year 2025 Adjusted EBITDA guidance Novanta Inc. (NASDAQ:NOVT) ("Novanta" or the "Company"), a trusted technology partner to medical and advanced technology equipment manufacturers, today reported financial results for the first quarter 2025. Financial Highlights Three Months Ended   (In millions, except per share amoun

Novanta Inc. (NASDAQ:NOVT) (the "Company"), a trusted technology partner to medical and advanced technology equipment manufacturers, will release its first quarter 2025 results on Tuesday, May 6, 2025. The Company will host a conference call on Tuesday, May 6, 2025, at 10:00 a.m. ET to discuss these results. To access the call, please dial (888) 346-3959 before the scheduled conference call time. Alternatively, the conference call can be accessed online via a live webcast on the Events & Presentations page of the Investors section of the Company's website at www.novanta.com. A replay of the audio webcast will be available approximately three hours after the conclusion of the call on the E

Fourth Quarter 2024 GAAP Revenue increased 13% to $238 million, including $2 million unfavorable FX impact Fourth Quarter 2024 GAAP Diluted EPS of $0.46 and Adjusted EPS of $0.76 Full Year 2024 GAAP Revenue increased 8% to $949 million Full Year 2024 GAAP Diluted EPS of $1.77, and Adjusted EPS of $3.08 Full Year 2024 Adjusted EBITDA increased 7% to $210 million Full Year 2024 Operating Cash Flow increased 32% to $159 million Novanta Inc. (NASDAQ:NOVT) ("Novanta" or the "Company"), a trusted technology partner to medical and advanced technology equipment manufacturers, today reported financial results for the fourth quarter and full year 2024. Financial Highlights

Novanta Inc. (NASDAQ:NOVT) (the "Company"), a trusted technology partner to medical and advanced technology equipment manufacturers, will release its fourth quarter and full year 2024 results on Tuesday, February 25, 2025. The Company will host a conference call on Tuesday, February 25, 2025, at 10:00 a.m. ET to discuss these results. To access the call, please dial (888) 346-3959 before the scheduled conference call time. Alternatively, the conference call can be accessed online via a live webcast on the Events & Presentations page of the Investors section of the Company's website at www.novanta.com. A replay of the audio webcast will be available approximately three hours after the co

Third Quarter 2024 GAAP Revenue of $244 million Third Quarter 2024 GAAP Net Income of $19 million Third Quarter 2024 GAAP Diluted Earnings Per Share of $0.53 Third Quarter 2024 Adjusted Earnings Per Share of $0.85 Third Quarter 2024 Adjusted EBITDA of $57 million Novanta Inc. (NASDAQ:NOVT) ("Novanta" or the "Company"), a trusted technology partner to medical and advanced technology equipment manufacturers, today reported financial results for the third quarter 2024. Financial Highlights Three Months Ended   (In millions, except per share amounts) September 27,     September 29,     2024     2023   GAAP          

Novanta Inc. (NASDAQ:NOVT) (the "Company"), a trusted technology partner to medical and advanced technology equipment manufacturers, will release its third quarter 2024 results on Tuesday, November 5, 2024. The Company will host a conference call on Tuesday, November 5, 2024, at 10:00 a.m. ET to discuss these results. To access the call, please dial (888) 346-3959 before the scheduled conference call time. Alternatively, the conference call can be accessed online via a live webcast on the Events & Presentations page of the Investors section of the Company's website at www.novanta.com. A replay of the audio webcast will be available approximately three hours after the conclusion of the cal